Busca avançada
Ano de início
Entree
(Referência obtida automaticamente do Web of Science, por meio da informação sobre o financiamento pela FAPESP e o número do processo correspondente, incluída na publicação pelos autores.)

Increased expression of tissue inhibitor of metalloproteinase-1 correlates with improved outcome in canine cutaneous mast cell tumours

Texto completo
Autor(es):
Pulz, L. H. ; Barra, C. N. ; Kleeb, S. R. ; Xavier, J. G. ; Catao-Dias, J. L. ; Sobral, R. A. ; Fukumasu, H. ; Strefezzi, R. F.
Número total de Autores: 8
Tipo de documento: Artigo Científico
Fonte: VETERINARY AND COMPARATIVE ONCOLOGY; v. 15, n. 2, p. 606-614, JUN 2017.
Citações Web of Science: 7
Resumo

Canine mast cell tumour (MCT) is a biologically heterogeneous disease. The extracellular matrix degradation promoted by matrix metalloproteinases (MMPs) has been studied in an attempt to elucidate the mechanisms involved in the biological behaviour of tumours. The aim of this study was to characterize the expression of MMP-2 and -9 and tissue inhibitors of metalloproteinase (TIMP)-1 and -2 in canine cutaneous MCTs and to evaluate their prognostic values. Immunohistochemical staining for MMP-2, MMP-9, TIMP-2 and TIMP-1 was performed in 46 canine cases of MCTs. TIMP-1 expression showed an independent prognostic value for post-surgical survival and disease-related mortality. Dogs with MCTs showing less than 22.9% mast cell TIMP-1 positivity were more prone to die because of the disease and had a shorter post-surgical survival. This article suggests the involvement of TIMP-1 in MCT progression, by contributing to a good outcome in patients with MCTs. (AU)

Processo FAPESP: 10/05094-5 - Avaliação imuno-histoquímica das expressões de VEGF, VEGFR e metaloproteinase 9 como potenciais indicadores prognósticos para mastocitomas cutâneos caninos
Beneficiário:Ricardo de Francisco Strefezzi
Modalidade de apoio: Auxílio à Pesquisa - Regular
Processo FAPESP: 13/13252-8 - Caracterização de genes relacionados à apoptose em mastocitomas cutâneos caninos e seu valor como indicador prognóstico
Beneficiário:Ricardo de Francisco Strefezzi
Modalidade de apoio: Auxílio à Pesquisa - Regular